Susquehanna International Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.5M | Sell |
415,200
-187,700
| -31% | -$10.9M | ﹤0.01% | 2030 |
|
|
2025
Q4 | $35.8M | Buy |
602,900
+44,600
| +8% | +$2.43M | ﹤0.01% | 1647 |
|
|
2025
Q3 | $30.2M | Buy |
558,300
+259,600
| +87% | +$14.8M | ﹤0.01% | 1788 |
|
|
2025
Q2 | $16.4M | Sell |
298,700
-6,300
| -2% | -$371K | ﹤0.01% | 2221 |
|
|
2025
Q1 | $21.6M | Sell |
305,000
-495,300
| -62% | -$33.3M | ﹤0.01% | 1681 |
|
|
2024
Q4 | $52.6M | Buy |
800,300
+524,900
| +191% | +$35.2M | 0.01% | 1080 |
|
|
2024
Q3 | $19.4M | Buy |
275,400
+76,900
| +39% | +$6.43M | ﹤0.01% | 1860 |
|
|
2024
Q2 | $16.3M | Sell |
198,500
-14,300
| -7% | -$1.19M | ﹤0.01% | 1944 |
|
|
2024
Q1 | $18.6M | Buy |
212,800
+48,600
| +30% | +$4.35M | ﹤0.01% | 1862 |
|
|
2023
Q4 | $15.8M | Buy |
164,200
+51,700
| +46% | +$4.57M | ﹤0.01% | 2054 |
|
|
2023
Q3 | $9.95M | Sell |
112,500
-108,800
| -49% | -$9.68M | ﹤0.01% | 2580 |
|
|
2023
Q2 | $19.2M | Sell |
221,300
-25,600
| -10% | -$2.41M | ﹤0.01% | 1765 |
|
|
2023
Q1 | $24M | Buy |
246,900
+24,300
| +11% | +$2.52M | 0.01% | 1521 |
|
|
2022
Q4 | $23M | Buy |
222,600
+143,300
| +181% | +$13.5M | 0.01% | 1403 |
|
|
2022
Q3 | $6.72M | Buy |
79,300
+14,300
| +22% | +$1.27M | ﹤0.01% | 2716 |
|
|
2022
Q2 | $5.39M | Sell |
65,000
-105,000
| -62% | -$8.36M | ﹤0.01% | 3067 |
|
|
2022
Q1 | $13.1M | Sell |
170,000
-89,800
| -35% | -$7.51M | ﹤0.01% | 2201 |
|
|
2021
Q4 | $23M | Sell |
259,800
-99,100
| -28% | -$8.18M | ﹤0.01% | 1721 |
|
|
2021
Q3 | $27.7M | Sell |
358,900
-28,300
| -7% | -$2.23M | ﹤0.01% | 1658 |
|
|
2021
Q2 | $32.3M | Sell |
387,200
-123,800
| -24% | -$9.81M | ﹤0.01% | 1538 |
|
|
2021
Q1 | $38.6M | Buy |
511,000
+150,400
| +42% | +$12.3M | 0.01% | 1298 |
|
|
2020
Q4 | $31.6M | Buy |
360,600
+8,700
| +2% | +$690K | 0.01% | 1328 |
|
|
2020
Q3 | $26.8M | Buy |
351,900
+39,800
| +13% | +$4.03M | 0.01% | 1245 |
|
|
2020
Q2 | $38.5M | Sell |
312,100
-41,100
| -12% | -$4.08M | 0.01% | 972 |
|
|
2020
Q1 | $29.8M | Sell |
353,200
-162,600
| -32% | -$14M | 0.01% | 944 |
|
|
2019
Q4 | $43.6M | Sell |
515,800
-100,400
| -16% | -$7.58M | 0.01% | 896 |
|
|
2019
Q3 | $41.5M | Sell |
616,200
-17,600
| -3% | -$1.36M | 0.01% | 845 |
|
|
2019
Q2 | $54.3M | Buy |
633,800
+186,000
| +42% | +$15.9M | 0.02% | 649 |
|
|
2019
Q1 | $39.8M | Buy |
447,800
+149,000
| +50% | +$13.8M | 0.02% | 748 |
|
|
2018
Q4 | $25.4M | Sell |
298,800
-1,900
| -0.6% | -$181K | 0.01% | 942 |
|
|
2018
Q3 | $29.2M | Buy |
300,700
+117,300
| +64% | +$11.7M | 0.01% | 1038 |
|
|
2018
Q2 | $17.3M | Sell |
183,400
-153,800
| -46% | -$13.5M | 0.01% | 1414 |
|
|
2018
Q1 | $27.3M | Sell |
337,200
-228,300
| -40% | -$19.6M | 0.01% | 1003 |
|
|
2017
Q4 | $50.4M | Buy |
565,500
+262,400
| +87% | +$22.8M | 0.02% | 690 |
|
|
2017
Q3 | $28.2M | Sell |
303,100
-77,300
| -20% | -$6.83M | 0.01% | 988 |
|
|
2017
Q2 | $34.5M | Buy |
380,400
+8,100
| +2% | +$737K | 0.02% | 802 |
|
|
2017
Q1 | $32.7M | Sell |
372,300
-144,200
| -28% | -$12.8M | 0.02% | 771 |
|
|
2016
Q4 | $42.8M | Sell |
516,500
-129,000
| -20% | -$11.1M | 0.02% | 622 |
|
|
2016
Q3 | $59.7M | Sell |
645,500
-4,900
| -0.8% | -$461K | 0.03% | 483 |
|
|
2016
Q2 | $50.6M | Buy |
650,400
+213,800
| +49% | +$18.2M | 0.03% | 509 |
|
|
2016
Q1 | $36M | Buy |
436,600
+22,700
| +5% | +$1.85M | 0.02% | 666 |
|
|
2015
Q4 | $43.4M | Sell |
413,900
-58,200
| -12% | -$6.08M | 0.02% | 670 |
|
|
2015
Q3 | $49.7M | Sell |
472,100
-273,000
| -37% | -$36.5M | 0.02% | 632 |
|
|
2015
Q2 | $102M | Buy |
745,100
+251,600
| +51% | +$31.2M | 0.04% | 392 |
|
|
2015
Q1 | $61.5M | Buy |
493,500
+345,700
| +234% | +$36.6M | 0.03% | 540 |
|
|
2014
Q4 | $13.4M | Sell |
147,800
-25,000
| -14% | -$2.08M | 0.01% | 1706 |
|
|
2014
Q3 | $12.5M | Sell |
172,800
-165,000
| -49% | -$10.8M | ﹤0.01% | 1869 |
|
|
2014
Q2 | $21M | Buy |
337,800
+38,200
| +13% | +$2.31M | 0.01% | 1359 |
|
|
2014
Q1 | $20.4M | Sell |
299,600
-63,000
| -17% | -$4.64M | 0.01% | 1257 |
|
|
2013
Q4 | $25.5M | Buy |
362,600
+236,800
| +188% | +$16.1M | 0.01% | 1127 |
|
|
2013
Q3 | $9.09M | Buy |
125,800
+26,800
| +27% | +$1.78M | ﹤0.01% | 2008 |
|
|
2013
Q2 | $5.52M | Buy |
+99,000
| New | +$6.17M | ﹤0.01% | 2489 |
|
Other funds holding BMRN
VCM
VPM
Susquehanna International Group's BMRN Position: Q1 2026 in Review
Susquehanna International Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 87% in Q1 2026, selling an estimated $7.04M and leaving 18,513 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #7776.
Susquehanna International Group first reported a position in BMRN in Q2 2013 and has held it in 49 quarters since. The position peaked at $59.1M in Q1 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Susquehanna International Group held 18,513 shares of BioMarin Pharmaceuticals worth $1.05M as of Q1 2026.
- Susquehanna International Group sold 120,697 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $7.04M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7776 holding.
- Susquehanna International Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
- Susquehanna International Group's BioMarin Pharmaceuticals position peaked at $59.1M in Q1 2024.
- 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.